The interaction of WB4101, and other alpha-adrenoceptor antagonists, on 5-hydroxytryptamine receptors.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D001679:Biogenic Amines / Q000494:pharmacology; D004146:Dioxanes / Q000494:pharmacology*; D004147:Dioxins / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D013948:Moxisylyte / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D010646:Phentolamine / Q000494:pharmacology; D010647:Phenyl Ethers / Q000494:pharmacology; D051381:Rats; D011985:Receptors, Serotonin / Q000187:drug effects*; D013270:Stomach / Q000187:drug effects; D014649:Vas Deferens / Q000187:drug effects; D015016:Yohimbine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D001679:Biogenic Amines; D004146:Dioxanes; D004147:Dioxins; D010647:Phenyl Ethers; D011985:Receptors, Serotonin; D015016:Yohimbine; C010654:(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane; D013948:Moxisylyte; D010646:Phentolamine